LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
Lindis Biotech GmbH / Key word(s): Regulatory Approval LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES 13.02.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement.
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLYLINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES
CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER
UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE EXCLUSIVE RIGHTS TO BRING CATUMAXOMAB TO MARKET AND TO LEAD ALL ACTIVITIES TO LAUNCH CATUMAXOMAB ACROSS EUROPE
THIS MARKS ANOTHER MILESTONE FOR PHARMANOVIA, AS IT DEEPENS ITS FOOTPRINT WITHIN SPECIALTY PHARMACEUTICALS
MUNICH, GERMANY, AND BASILDON, UK, 13 February 2025LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline in immuno-oncology, and Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, today announced that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.Under a licensing agreement, LINDIS has granted Pharmanovia the exclusive rights to bring catumaxomab to market and spearhead its launch across Europe.Catumaxomab, a first-in-class therapeutic, is specifically designed to treat malignant ascites in adults with certain types of cancer (epithelial cellular adhesion molecule (EpCAM)-positive carcinomas) who are not eligible for other systemic anticancer therapies. Malignant ascites is a serious complication of advanced-stage cancers, characterised by the buildup of fluid in the abdomen, causing significant discomfort and severely impacting quality of life. The condition leads to considerable symptoms such as abdominal distension, pain, shortness of breath, fatigue, and fever.Stephen Deacon, Chief Scientific Officer at Pharmanovia commented; 'This European Commission approval of catumaxomab is a significant milestone for people living with malignant ascites.Catumaxomab represents a novel therapeutic approach to this challenging condition. By targeting tumour cells and harnessing the power of the patient's own immune system, we aim to improve quality of life for those living with malignant ascites in Europe."Pharmanovia CEO, Dr. James Burt, highlighted the broader implications of the approval; 'This approval not only brings a much-needed treatment to people with malignant ascites but also exemplifies Pharmanovia's commitment to deepening our footprint within the specialty pharmaceutical sector. We are dedicated to delivering innovative and improved medicines to people in need, and this approval reinforces our position as a leader in providing access to essential therapies."Dr. Horst Lindhofer, Chief Executive Officer of Lindis Biotech, added: 'We are delighted to receive marketing approval for catumaxomab. The approval highlights its potential to address the significant medical and treatment challenges faced by patients with malignant ascites. These individuals often endure invasive procedures like paracentesis, which carry risks of complications and severely impact their quality of life. Partnering with Pharmanovia to support commercialization, we are committed to ensuring that this groundbreaking therapy becomes accessible to all patients who can benefit from it.'-Ends-Notes to editorsAbout PharmanoviaPharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences.With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.Lindis BiotechLindis Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific trifunctional antibodies, empowering the immune system to turn malignant cancers into manageable and possibly curable diseases.About CATUMAXOMABCatumaxomab was originally granted marketing authorisation under the brand name Removab in the EU on 20 April 2009 for treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. The product has not been marketed since 2014 and on 2 June 2017 the product was withdrawn from the EU due to commercial reasons.On 17th October Lindis Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) with the brand name KORJUNY®.Catumaxomab effectively destroys cancer cells by attaching to two antigens: EpCAM and CD3 to form a bridge between the cancer cells and the T-cells. This brings the cells close together so that the T-cells can kill the cancer cells. Catumaxomab also attaches and activates Fc-gamma receptor positive immune cells like e.g. monocytes and macrophages, which also helps the body's immune system to not only attack and destroy cancer cells, but also potentially induce a vaccination effect. ,The EpCAM marker is a tumor associated antigen highly expressed on almost all carcinomas (as e.g. gastric-, colorectal-, ovarian-, prostate-, pancreas-, bladder-, lung- and endometrial cancer) and is also known as a marker on tumor initiating cancer stem cells – a main driver of metastasis. Therefore, it is a promising approach for targeted treatment of various carcinomas.For more information please contact: Pharmanovia Alison Dyson Director of Communications, Pharmanovia Tel.: 07912887250 E-Mail: orLINDIS Biotech GmbH Dr. Horst Lindhofer CEO E-Mail: Website:Media inquiries MC Services AG Anne Hennecke Tel.: +49 (0) 211-529-252-22 E-Mail:References Korjuny | European Medicines Agency (EMA) (2024) European Medicines Agency (EMA). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny (Accessed: 11 December 2024). Ascites and Cancer - Side Effects (2024) Cancer.gov. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/ascites#signs-and-symptoms-of-ascites (Accessed: 11 December 2024). Atanackovic et al., Human Vaccines & Immunotherapeutics 9:12, 1–10; 2013
13.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Europe, we're not leaving. Period.
There are some headlines making the rounds claiming that TechCrunch is 'pulling out of Europe' and shuttering its coverage of European startups. This is flat-out wrong. It misrepresents who we are, what we do, and — most of all — what we believe. The recent changes at TechCrunch are not about retreat. They are about realignment and reinforcement. This new chapter is fueled by our partnership with our sister company, Foundry, which was brought under the same ownership to create a tech media entity with unparalleled global scope. To be clear, Foundry is a powerhouse of international technology journalism. Its portfolio includes established and respected brands like PCWorld, Macworld, CIO, and TechAdvisor, with a vast network of journalists and deep-rooted expertise in local and regional tech ecosystems across Europe and the world. The suggestion that our new ownership believes international coverage is unessential is patently false. The entire purpose of bringing TechCrunch and Foundry together is to create a stronger, more globally focused media platform. Europe is where fintech regulation is rewritten, where quantum startups spin out of Max Planck labs, where climate-tech pilots become the standard for the rest of the planet. In 2024 alone, European founders raised over €40 billion; many of the unicorns we covered last year were born on this continent. If you care about the future of technology, you have to be here. And we are. As we integrate the strengths of both TechCrunch and Foundry, here is our promise to the founders, investors, and readers in Europe and beyond: To the startup community: Keep your tips, term sheets, and tantrums coming. Send them to tips@ or ping our encrypted channels. We'll be listening — louder and more broadly than ever. TechCrunch isn't retreating from Europe. We're doubling down. — Michael Reinstein, Chairman and Publisher Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Julius Baer Successfully Places EUR 500 Million Senior Unsecured Notes
ZURICH - June 11, 2025 (NEWMEDIAWIRE) - Today, Julius Baer Group Ltd. successfully placed EUR 500 million 5-year senior unsecured notes through ELM B.V., a repackaging issuance entity incorporated in the Netherlands. This EUR senior unsecured issuance allows Julius Baer to further diversify its funding strategy in international debt markets. The transaction was targeted at European institutional investors and the proceeds will be used for general corporate purposes. Julius Baer Group Ltd. will issue loan notes to, and which are held by, ELM B.V. (or a nominee acting on its behalf), which in turn will issue its own notes to investors secured by the Julius Baer Group Ltd. loan notes. The securities carry a fixed-rate, annually payable coupon set at 3.375% per annum and have been issued in denominations of EUR 100,000. An application for admission to trading of the notes issued by ELM B.V. on Euronext Dublin will be made. ContactsMedia Relations, tel. +41 (0) 58 888 8888Investor Relations, tel. +41 (0) 58 888 5256 This announcement is not and shall not be interpreted or construed as a solicitation to purchase any securities of/in Julius Baer Group. About Julius Baer Julius Baer is the leading Swiss wealth management group and a premium brand in this global sector, with a focus on servicing and advising sophisticated private clients. In all we do, we are inspired by our purpose: creating value beyond wealth. At the end of April 2025, assets under management amounted to CHF 467 billion. Bank Julius Baer & Co. Ltd., the renowned Swiss private bank with origins dating back to 1890, is the principal operating company of Julius Baer Group Ltd., whose shares are listed on the SIX Swiss Exchange (ticker symbol: BAER) and are included in the Swiss Leader Index (SLI), comprising the 30 largest and most liquid Swiss stocks. Julius Baer is present in around 25 countries and 60 locations. Headquartered in Zurich, we have offices in key locations including Bangkok, Dubai, Dublin, Frankfurt, Geneva, Hong Kong, London, Luxembourg, Madrid, Mexico City, Milan, Monaco, Mumbai, Santiago de Chile, Shanghai, Singapore, Tel Aviv, and Tokyo. Our client-centric approach, our objective advice based on the Julius Baer open product platform, our solid financial base, and our entrepreneurial management culture make us the international reference in wealth management. For more information visit our website at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Farmina Opens First U.S. Manufacturing Facility in Reidsville, North Carolina
Family-Owned Italian Pet Food Company Invests $115M Creating Hundreds of Jobs in Rockingham County REIDSVILLE, N.C., June 11, 2025 /PRNewswire/ -- Farmina Pet Foods, a global leader in premium pet nutrition, officially opened its first U.S.-based manufacturing facility in Reidsville, North Carolina marking a major milestone in the company's 50-year history. While new to U.S. manufacturing, Farmina has served North American pet owners for more than a decade, delivering premium pet food made with European ingredients, upheld by rigorous standards and cutting-edge technology. The 150,000-square-foot state-of-the-art manufacturing facility, located at 248 Sands Road, Reidsville, represents a $115 million investment and is expected to create 200 new jobs over the next five years, with 75 positions already filled. New roles include machine operators, veterinarians, chemical technicians, shipping clerks, maintenance technicians, managers, and supervisors. To celebrate Farmina's investment in the local and state economies, North Carolina State Senator Phil Berger, Assistant Commissioner for Consumer Protection, NC Department of Agriculture Chrissy Waggett, Chairman of the Rockingham County board of Commissioners Kevin Berger, and Mayor of Reidsville Donald Gorham, attended the official opening of the facility on June 11, 2025. Senator Phil Berger welcomed the expansion, stating "Farmina's decision to establish its U.S. operations in North Carolina is a strong endorsement of our skilled workforce and our growing reputation as a business-friendly hub for modern, innovative manufacturing." He continued, "We're thrilled to welcome this world-class technology to our great state and proudly open our arms to Farmina as they join our business community." The company's strategic investment in North Carolina is expected to contribute millions of dollars to the state's economy. Farmina's decision to manufacture in the U.S. allows the company to localize production, serving the growing North American market faster and more sustainably. Farmina sets a new standard in the American-based pet food industry with respect to quality and technology. This expansion brings unmatched excellence in manufacturing technology, quality of ingredients and European food safety and nutrition standards that adhere to and far exceed U.S. regulations. Through the production output of this new facility, Farmina sets a new standard of pet care for consumers across North America. "As Italians, family is at the heart of everything we do – and that includes our pets," said Loris Rinaldi, CEO of Farmina Pet Foods North America. "This belief drives us to create the highest quality nutrition for our four-legged family members. With our new Reidsville facility, we're proud to bring European standards, premium ingredients, and personalized support to pet parents across the U.S." The high-tech facility was years in the making and supported by a coalition including the North Carolina Department of Commerce, Rockingham County, the City of Reidsville, Duke Energy, and the Economic Development Partnership of North Carolina (EDPNC), with assistance from the state's Job Development Investment Grant (JDIG). To learn more about Farmina and its premier nutritional pet food products, visit: About Farmina Pet FoodsFarmina Pet Foods is a family-owned company that combines nature and science to create the most nutritious, all-natural, and scientifically validated pet food. With over 50 years of expertise, Farmina is dedicated to improving the well-being of pets by using carefully selected raw ingredients that meet the nutritional needs of dogs and cats. Guided by the philosophy of "Happy Pet, Happy You," Farmina ensures its products are free from GMOs, preserved using natural methods, and developed in collaboration with leading research institutions, such as Cornell University. Farmina goes beyond nutrition by offering personalized services to pet parents, including expert nutritional consultations and tailored meal plans to support pets at every stage of life. With North American headquarters in Reidsville, NC, Farmina provides pet families with specialized food lines, such as Farmina Vet Life and Natural & Delicious, all designed to promote the health and happiness of pets. View original content to download multimedia: SOURCE Farmina Pet Foods Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data